Hong Kong, Macao Block Use Of Allopurinol After Five Deaths
This article was originally published in PharmAsia News
Macao and Hong Kong authorities have taken action against the allopurinol gout drug made by Europharm Laboratories following five death reports. Macao ordered the drug recalled and imports blocked while Hong Kong SAR's Health Department urged a halt to use of the drug. Batches made by the Hong Kong-based pharma were discovered to have been tainted with fungal contamination. Health authorities in Hong Kong, where about 40,000 patients have received the drug, said they found a bacteria mucormycosis level in some batches 100 times more than the standard amount. (Click here for more
You may also be interested in...
The US FDA released five device-related close-out letters in March.
Governments around the world should designate all medicines as ‘priority essential products’, the IGBA has urged, as a surge in demand coinciding with a reduction in the number of flights and rising freight costs are making it more difficult for suppliers to meet global requirements amid the coronavirus pandemic.
In a letter to the medtech industry, the FDA’s William Maisel says the US agency will hold remote meetings with device makers and other stakeholders through the end of May. The FDA also extended due dates for marketing applications by 90 days.